1
|
Coca-Pelaz A, Rodrigo JP, Bradley PJ,
Vander Poorten V, Triantafyllou A, Hunt JL, Strojan P, Rinaldo A,
Haigentz M Jr, Takes RP, et al: Adenoid cystic carcinoma of the
head and neck - An update. Oral Oncol. 51:652–661. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
International Head; Neck Scientific Group,
: Cervical lymph node metastasis in adenoid cystic carcinoma of the
sinonasal tract, nasopharynx, lacrimal glands and external auditory
canal: A collective international review. J Laryngol Otol.
130:1093–1097. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Togashi Y, Dobashi A, Sakata S, Sato Y,
Baba S, Seto A, Mitani H, Kawabata K and Takeuchi K: MYB and MYBL1
in adenoid cystic carcinoma: Diversity in the mode of genomic
rearrangement and transcripts. Mod Pathol. 31:934–946. 2018.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu
JJ, Rui JA, Wei X and Ye DX: Molecular cloning and characterization
of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma.
Oncogene. 22:5060–5069. 2003. View Article : Google Scholar : PubMed/NCBI
|
5
|
Liu X, Xiong F, Wei X, Yang H and Zhou R:
LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif
play critical roles in proliferation and metastatic potential of
hepatocellular carcinoma cells. Cancer Sci. 100:2335–2340. 2009.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Liu XR, Zhou RL, Zhang QY, Zhang Y, Jin
YY, Lin M, Rui JA and Ye DX: Structure analysis and expressions of
a novel tetratransmembrane protein, lysosoma-associated protein
transmembrane 4 beta associated with hepatocellular carcinoma.
World J Gastroenterol. 10:1555–1559. 2004. View Article : Google Scholar : PubMed/NCBI
|
7
|
Yang H, Xiong F, Qi R, Liu Z, Lin M, Rui
J, Su J and Zhou R: LAPTM4B-35 is a novel prognostic factor of
hepatocellular carcinoma. J Surg Oncol. 101:363–369. 2010.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Yang H, Xiong FX, Lin M, Yang Y, Nie X and
Zhou RL: LAPTM4B-35 overexpression is a risk factor for tumor
recurrence and poor prognosis in hepatocellular carcinoma. J Cancer
Res Clin Oncol. 136:275–281. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Zhou L, He XD, Chen J, Cui QC, Qu Q, Rui
JA and Zhao YP: Overexpression of LAPTM4B-35 closely correlated
with clinicopathological features and post-resectional survival of
gallbladder carcinoma. Eur J Cancer. 43:809–815. 2007. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kang Y, Yin M, Jiang W, Zhang H, Xia B,
Xue Y and Huang Y: Overexpression of LAPTM4B-35 is associated with
poor prognosis in colorectal carcinoma. Am J Surg. 204:677–683.
2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Yin M, Li C, Li X, Lou G, Miao B, Liu X,
Meng F, Zhang H, Chen X, Sun M, et al: Over-expression of LAPTM4B
is associated with poor prognosis and chemotherapy resistance in
stages III and IV epithelial ovarian cancer. J Surg Oncol.
104:29–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Yang Y, Yang H, McNutt MA, Xiong F, Nie X,
Li L and Zhou R: LAPTM4B overexpression is an independent
prognostic marker in ovarian carcinoma. Oncol Rep. 20:1077–1083.
2008.PubMed/NCBI
|
13
|
Tang H, Tian H, Yue W, Li L, Li S, Gao C,
Si L, Qi L and Lu M: Overexpression of LAPTM4B is correlated with
tumor angiogenesis and poor prognosis in non-small cell lung
cancer. Med Oncol. 31:9742014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kong F, Gao F, Chen J, Sun Y, Zhang Y, Liu
H, Li X, Yang P, Zheng R, Liu G, et al: Overexpressed LAPTM4B-35 is
a risk factor for cancer recurrence and poor prognosis in
non-small-cell lung cancer. Oncotarget. 7:56193–56199. 2016.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Zhang H, Wei Q, Liu R, Qi S, Liang P, Qi
C, Wang A, Sheng B, Li L and Xu Y: Overexpression of LAPTM4B-35: A
novel marker of poor prognosis of prostate cancer. PLoS One.
9:e910692014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Meng FL, Yin MZ, Song HT, Yang H, Lou G
and Zhou RL: LAPTM4B-35 overexpression is an independent prognostic
marker in endometrial carcinoma. Int J Gynecol Cancer. 20:745–750.
2010. View Article : Google Scholar : PubMed/NCBI
|
17
|
Cheng X, Zheng Z, Bu Z, Wu X, Zhang L,
Xing X, Wang X, Hu Y, Du H, Li L, et al: LAPTM4B-35, a
cancer-related gene, is associated with poor prognosis in TNM
stages I–III gastric cancer patients. PLoS One. 10:e01215592015.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Liu L, Xu X, Jing L, Zhou G, Cao Z, Han Y
and Zhou R: Lysosomal-associated protein transmembrane 4 Beta-35
overexpression is a novel independent prognostic marker for gastric
carcinoma. PLoS One. 10:e01180262015. View Article : Google Scholar : PubMed/NCBI
|
19
|
Amit M, Binenbaum Y, Sharma K, Ramer N,
Ramer I, Agbetoba A, Glick J, Yang X, Lei D, Bjørndal K, et al:
Incidence of cervical lymph node metastasis and its association
with outcomes in patients with adenoid cystic carcinoma. An
international collaborative study. Head Neck. 37:1032–1037. 2015.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Amit M, Binenbaum Y, Trejo-Leider L,
Sharma K, Ramer N, Ramer I, Agbetoba A, Miles B, Yang X, Lei D, et
al: International collaborative validation of intraneural invasion
as a prognostic marker in adenoid cystic carcinoma of the head and
neck. Head Neck. 37:1038–1045. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Šteiner P, Andreasen S, Grossmann P, Hauer
L, Vaněček T, Miesbauerová M, Santana T, Kiss K, Slouka D and
Skálová A: Prognostic significance of 1p36 locus deletion in
adenoid cystic carcinoma of the salivary glands. Virchows Arch.
473:471–480. 2018. View Article : Google Scholar : PubMed/NCBI
|
22
|
Ferrarotto R, Mitani Y, Diao L, Guijarro
I, Wang J, Zweidler- McKay P, Bell D, William WN Jr, Glisson BS,
Wick MJ, et al: Activating NOTCH1 mutations define a distinct
subgroup of patients with adenoid cystic carcinoma who have poor
prognosis, propensity to bone and liver metastasis, and potential
responsiveness to Notch1 inhibitors. J Clin Oncol. 35:352–360.
2017. View Article : Google Scholar : PubMed/NCBI
|
23
|
Li ZR: LAPTM4B: A novel diagnostic
biomarker and therapeutic target for hepatocellular carcinoma.
Hepatocellular Carcinoma. Lau WY: InTech Press; Melbourne, FL: pp.
1–34. 2012
|
24
|
Yang H, Xiong F, Wei X, Yang Y, McNutt MA
and Zhou R: Overexpression of LAPTM4B-35 promotes growth and
metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer
Lett. 294:236–244. 2010. View Article : Google Scholar : PubMed/NCBI
|